gene therapy
Alexion vs Novartis Rare Disease Data Center Power Play
Yes, Alexion’s portfolio gains at AAN 2026 - four new orphan approvals and a 17% portfolio expansion - have shifted the rare-disease market and are reshaping investor expectations. The company’s newly integrated rare disease data center cut pre-clinical lead times by 42%, according to internal audit metrics. Analysts